American Journal of Epidemiology Vol. 139, No. 7: 670-683
Copyright © 1994 by The Johns Hopkins University School of Hygiene and Public Health
other |
Menopausal Hormone Usage and Breast Cancer in Saskatchewan: A Record-Linkage Cohort Study
1Department of Epidemiology and Public Health Yale University School of Medicine New Haven CT
2National Cancer Institute of Canada Epidemiology Unit Department of Preventive Medicine and Biostatistics University of Toronto Toronto Ontario Canada
Reprint requests to Dr. Harvey A. Rlsch, Department of Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, P.O. Box 3333,New Haven, CT 06510
The association between the occurrence of carcinoma of the breast and previous usage of menopausal estrogens, progestins, and oral contraceptives is examined in a record-linkage study using the Saskatchewan Health Prescription-Drug-Plan Database. Saskatchewan Health is a governmental agency that funds publicly insured health care for essentially all residents of the province. For this study, all women aged 43–49 years in 1976 resident in Saskatchewan were identified from the Saskatthewan Health master registration file. These women were linked by registration beneficiary number to the Drug-Plan Database for the period from January 1976 to June 1987 and to the Provincial Cancer Registry Database for the period from March 1960 to December 1990. The fact and date of death or emigration from the province were obtained through the annual updates of the health plan. Of the 33,003 women initially in the cohort, 213 had a breast cancer diagnosed before 1976 and were omitted from this analysis. Between 1976 and 1990, 742 new primary breast cancer cases occurred. Women taking estrogens unopposed by progestins had an elevated risk of breast cancer, the risk increasing by 7% (relative risk = 1.072, 95% confidence interval 1.02–1.13; p = 0.008) for each 252 tablets used (approximately 1 year of use). Usage of estrogens opposed by progestins showed no association with risk (p = 0.48). Women taking oral contraceptives during this follow-up period also had a higher risk, increasing by 14% (relative risk = 1.144, 95% confidence interval 1.05–1.24; p= 0.002) for every 252 tablets used. These 1-year risk elevations are small but become appreciable at longer durations. For example, at 5 years of unopposed estrogen use, the relative risk is 1.42; for 5 years of oral contraceptive use, it is 1.96.
breast neoplasms; contraceptives; oral; estrogens; progestational hormones; prospective studies
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. W Wong, R. D Lewis, F. M Steinberg, M. J Murray, M. A Cramer, P. Amato, R. L Young, S. Barnes, K. J Ellis, R. J Shypailo, et al. Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial Am. J. Clinical Nutrition, November 1, 2009; 90(5): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials Hum. Reprod. Update, November 1, 2005; 11(6): 561 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cotterchio, N. Kreiger, B. Theis, M. Sloan, and S. Bahl Hormonal Factors and the Risk of Breast Cancer According to Estrogen- and Progesterone-Receptor Subgroup Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1053 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Newcomb, L. Titus-Ernstoff, K. M. Egan, A. Trentham-Dietz, J. A. Baron, B. E. Storer, W. C. Willett, and M. J. Stampfer Postmenopausal Estrogen and Progestin Use in Relation to Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 593 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Chen, N. S. Weiss, P. Newcomb, W. Barlow, and E. White Hormone Replacement Therapy in Relation to Breast Cancer JAMA, February 13, 2002; 287(6): 734 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hedblad, J. Merlo, J. Manjer, G. Engstrom, G. Berglund, and L. Janzon Incidence of cardiovascular disease, cancer and death in postmenopausal women affirming use of hormone replacement therapy Scand J Public Health, January 1, 2002; 30(1): 12 - 19. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. Santen, J. Pinkerton, C. McCartney, and G. R. Petroni Risk of Breast Cancer with Progestins in Combination with Estrogen as Hormone Replacement Therapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 16 - 23. [Full Text]
|
|
|
|
 |
|
 S. A. Narod, H. Risch, R. Moslehi, A. Dorum, S. Neuhausen, H. Olsson, D. Provencher, P. Radice, G. Evans, S. Bishop, et al. Oral Contraceptives and the Risk of Hereditary Ovarian Cancer N. Engl. J. Med., August 13, 1998; 339(7): 424 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Stanford, N. S. Weiss, L. F. Voigt, J. R. Daling, L. A. Habel, and M. A. Rossing Combined Estrogen and Progestin Hormone Replacement Therapy in Relation to Risk of Breast Cancer in Middle-aged Women JAMA, July 12, 1995; 274(2): 137 - 142. [Abstract] [PDF]
|
|
|
|
|
|
H.-O. Adami and I. Persson Hormone Replacement and Breast Cancer: A Remaining Controversy? JAMA, July 12, 1995; 274(2): 178 - 179. [Abstract] [PDF]
|
|